CAP-1002 Cell Therapy Improves Arm, Heart Function in DMD

CAP-1002 Cell Therapy Improves Arm, Heart Function in DMD

307396

CAP-1002 Cell Therapy Improves Arm, Heart Function in DMD

Treatment with the investigational cell therapy CAP-1002 significantly improved arm and heart function in boys and young men at advanced stages of Duchenne muscular dystrophy (DMD), according to final data from the HOPE-2 clinical trial. The Phase 2 trial also “met various skeletal and cardiac endpoints [goals] suggesting clinically relevant slowing of disease progression,” Capricor Therapeutics, the company developing CAP-1002, said in a press release. This final trial data confirms the positive top-line results presented last year…

You must be logged in to read/download the full post.